Human podocyte cell line

This conditionally immortalised human podocyte cell line was originally developed by Prof. Moin Saleem and colleagues at the University of Bristol.

Uses

• General research and development
• Drug development
• Drug screening 

Benefits

• Human derived
• Physiologically relevant phenotype analogous to differentiated podocytes in vivo
• Homogenous and stable
• Used by academic and industry groups worldwide
• Straightforward and robust protocols for the development of cells in culture

Licensing Options

• Long-term, single payment licensing model
• Discounted rates for SMEs
• Available under MTA for academic use.

Podocytes are highly specialised, terminally differentiated cells with a complex cellular architecture. They are a critical component of glomerular filtration. Cell-cycle control, growth arrest and differentiation are key to the in-vivo biology of podocytes. 

The conditionally immortalised podocyte cell line allows an in-vitro process of maturation analogous to the development and maturation of podocytes in-vivo. The result is a homogenous, stable cell source that shows expression of key antigenic markers of differentiated in vivo podocytes. These include the novel podocyte proteins nephrin, podocin, CD2AP and synapodin. This robust cell line is extensively characterised and validated.